Terns Pharmaceuticals (TERN) announced encouraging early data from the ongoing dose escalation part of the Phase 1 CARDINAL study evaluating TERN-701 in patients with relapsed/refractory chronic myeloid leukemia, CML. TERN-701 is an investigational, oral, potent, small molecule allosteric BCR-ABL inhibitor being developed for patients with CML. CARDINAL is a global, multicenter, open-label, two-part Phase 1 clinical trial to evaluate the safety, pharmacokinetics, and efficacy of TERN-701 in patients with relapsed/refractory CML with or without BCR-ABL resistance mutations. Key efficacy highlights include: 88% of patients with baseline transcript greater than 1% had decreases in BCR-ABL on treatment, with 7 ongoing as of data cutoff; Cumulative MMR rate of 50% in non-T315i mutation patients with 3 or more months of treatment and/or MMR or better at baseline; 100% of patients with MMR or better at baseline have maintained their response and remain on treatment. Additional notable responses include: MR2 within 5 months in a 4L patient at 160mg QD with baseline transcript greater than 1% and suboptimal response and intolerance to asciminib; MR4 within 3 months in a 5L patient treated at 320mg with baseline transcript greater than10% and treatment failure on bosutinib at study entry
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TERN:
- Terns Pharmaceuticals Appoints Heather Turner to Board
- Terns Pharmaceuticals Reports Q3 Progress and Financials
- Terns Pharmaceuticals reports Q3 EPS (28c), consensus (32c)
- Wingstop upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls
- Terns Pharmaceuticals initiated with an Outperform at Oppenheimer
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
